Edition:
India

Cue Biopharma Inc (CUE.OQ)

CUE.OQ on NASDAQ Stock Exchange Capital Market

13.77USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$13.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$17.76
52-wk Low
$11.10

Summary

Name Age Since Current Position

Daniel Passeri

55 President, Chief Executive Officer

Rodolfo Chaparro

Executive Vice President - Head of Immunology

Ronald Seidel

Executive Vice President - Head of Research and Development

Colin Sandercock

61 2017 Senior Vice President, General Counsel

Mary Simcox

2017 Vice President - Translational Biology

Kenneth Pienta

2017 Acting Chief Medical Officer

Peter Kiener

64 Director

Steven McKnight

64 2017 Director

Barry Simon

52 Director

Biographies

Name Description

Daniel Passeri

Mr. Daniel R. Passeri M.Sc. J.D. serves as President, Chief Executive Officer of the Company. Dan Passeri is a seasoned biotechnology executive with over 20 years of experience managing drug discovery and development programs as well as business development activities on behalf of publicly traded companies, with deep experience in both oncology and strategic partnership generation. Prior to joining Cue Biopharma, Mr. Passeri served as President and Chief Executive Officer as well as Vice Chairman of the Board of Curis, Inc. Prior to joining Curis, he was employed by GeneLogic Inc., most recently as Senior Vice President, Corporate Development and Strategic Planning. Prior to his work at GeneLogic, Mr. Passeri served as Director of Technology Management at Boehringer Mannheim. Mr. Passeri received a J.D. from the National Law Center at George Washington University, an M.Sc. in Biotechnology from the Imperial College of Science, Technology and Medicine at the University of London and a B.S. in Biology from Northeastern University.

Rodolfo Chaparro

Mr. Rodolfo J. Chaparro, Ph.D. serves as Executive Vice President - Head of Immunology of the Company. Rodolfo Chaparro is co-founder of Cue Biopharma and co-inventor of Cue’s technologies. Dr. Chaparro has oversight of Cue’s immuno-oncology and autoimmunity research programs as well as Cue’s preclinical and early clinical development. Previously Dr. Chaparro was a research faculty member in the Department of Biochemistry at the Albert Einstein College of Medicine in New York. Dr. Chaparro possesses research expertise in molecular immunology and immunotherapeutics development and was Head of Immunology within its Macromolecular Therapeutics Development Facility (MTDF). Dr. Chaparro holds a B.S. in Biology from the University of California at Irvine and a Ph.D. in immunology from Stanford University.

Ronald Seidel

Mr. Ronald D. Seidel III Ph.D. serves as Executive Vice President - Head of Research and Development of the Company. Ron Seidel is co-founder of Cue Biopharma and co-inventor of Cue’s technologies. Dr. Seidel has oversight of daily company operations, including integrating R&D and intellectual property (IP) development strategy with operational capabilities and scientific direction. Specifically, he leverages expertise in molecular engineering towards the generation of new high value assets. Previously Dr. Seidel was a Research Assistant Professor of Biochemistry and Associate Director of the Macromolecular Therapeutic Development Facility (MTDF) at the Albert Einstein College of Medicine. The function of the MTDF was to leverage high throughput technologies for the development, analysis and production of protein-based therapeutics. Additionally, through the MTDF, Dr. Seidel was the Associate Director of Eukaryotic Protein Production at the Northeast BioDefense Center (NBC). He has also served as consultant to industry in biologics and protein production. Dr. Seidel holds a B.S. and Ph.D. in biochemistry from the University of Georgia. He did his post-doctoral work at the New York Structural Biology Center.

Colin Sandercock

Mr. Colin Sandercock, M.Sc., J.D. serves as Senior Vice President, General Counsel of the company. Colin Sandercock brings more than 30 years of experience advising life sciences companies on a broad range of legal matters, including domestic and international patent litigation, compliance, procurement, and licensing. Before joining Cue Biopharma, Sandercock was most recently a Partner at Perkins Coie since 2009. Prior to Perkins Coie, he held positions within legal firms including Proskauer Rose where he co-chaired the firm’s Life Science Practice Group; Heller Ehrman, where he co-chaired the firm’s Intellectual Property Practice Group; and Foley & Lardner, where he chaired the firm’s Chemical Practice Group. His technical experience includes life science, pharmaceutical compositions and biologics, organic and inorganic chemistries, as well as chemical and biochemical engineering. Sandercock has served as an adjunct professor of law at George Washington University Law School, lecturing on the licensing of intellectual property rights, and on the AAA Patent Advisory Committee for Patent Disputes. He received his J.D. from the Catholic University of America and received a M.Sc. in Engineering degree in Chemical and Biochemical Engineering from the University of Pennsylvania, and a B.S. in Chemistry and Mathematics from Moravian College.

Mary Simcox

Ms. Mary Simcox, Ph.D. serves as Vice President - Translational Biology of the company. Before joining Cue, Dr. Simcox held various leadership positions at Tarveda Therapeutics, FORMA Therapeutics and Roche. Prior to Tarveda, she was Director of Biology at FORMA, where she oversaw the protein homeostasis target project portfolio. In this role, she led the discovery efforts to characterize novel pathway biology to discover and characterize potent and selective small molecule inhibitors to progress toward clinical development. Prior to FORMA, she held several leadership roles at Roche, where she led several small molecule and antibody projects into clinical development, worked to understand the mechanisms of resistance to Zelboraf® and Avastin®, led translational work on an anti-TWEAK antibody, and led discovery programs for the development of small molecule inhibitors of VEGFR2 and CDK2. Her undergraduate and doctoral work were completed at the University of California at Davis, where she earned a B.S. in Biochemistry and a Ph.D. in Nutrition.

Kenneth Pienta

Dr. Kenneth Pienta, M.D. serves as Acting Chief Medical Officer of the company. Kenneth Pienta is a highly-respected leader in the understanding of cancer metastases and the role of the tumor microenvironment in cancer development and immunosuppression. Dr. Pienta is the Donald S. Coffey Professor of Urology, as well as a Professor of Oncology, Pharmacology and Molecular Sciences, and Chemical and Biomolecular Engineering at Johns Hopkins University. Currently, he is the Director of Research at the Brady Urological Institute and also serves as the co-Director of the Johns Hopkins Individualized Health Initiative (Hopkins inHealth) to better define the practice of precision medicine. He has been the principal investigator on numerous local and national clinical trials and has a proven track record in developing multi-disciplinary translational research programs, diagnostics, and therapeutics. Dr. Pienta is the author of more than 350 peer-reviewed articles, and is a two-time American Cancer Society Clinical Research Professor Award recipient. Dr. Pienta received a B.A. in human biology from Johns Hopkins University and an M.D. from the Johns Hopkins University School of Medicine, and is board certified in oncology.

Peter Kiener

Dr. Peter A. Kiener, Ph.D. serves as Director of the Company. Mr. Kiener has deep experience in both biologics and immunotherapy, and is currently the Chief Scientific Officer at Sucampo. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior to Ambrx, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation and as a member of the Board of Directors of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.

Steven McKnight

Dr. Steven L. McKnight, Ph.D. serves as Director of the company. Steven McKnight leads an active research laboratory at UT Southwestern Medical Center. Prior to his work there, Dr. McKnight was co-founder and Director of Biology at Tularik, Inc. Previously he was a Howard Hughes Medical Institute investigator at the Carnegie Institution of Washington. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Dr. McKnight served on the Board of Directors for Tularik from its inception through its acquisition by Amgen in 2004. He also co-founded and served as a board member for Cumbre, Inc., and Peloton Therapeutics. Dr. McKnight holds a B.S. in biology from The University of Texas at Austin and a Ph.D. in biology from the University of Virginia.

Barry Simon

Dr. Barry J. Simon, M.D. serves as Director of the Company. Mr. Simon is President and COO of Nantkwest since its inception. Dr. Simon previously held various senior level executive and advisory positions at Roche Labs, F. Hoffmann-La Roche (VTX: ROG), Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol, NorthSound Capital, LLC, and HealthPro BioVentures. He has broad experience with product and portfolio divestitures and acquisitions, strategic licensing and joint ventures in addition to commercial product launches, IND and BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He trained clinically in infectious diseases, anesthesiology and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.